Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has a beta value of 2.23 and has seen 1,366,970 shares traded in the last trading session. The company, currently valued at $1.36 Billion, closed the last trade at $9.63 per share which meant it gained $0.2 on the day or 2.67% during that session. The SGMO stock price is -38.42% off its 52-week high price of $13.33 and 50.05% above the 52-week low of $4.81. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.31 Million shares traded. The 3-month trading volume is 2.32 Million shares.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) trade information

Sporting 2.67% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Jul 02 when the SGMO stock price touched $9.69-0 or saw a rise of 0.62%. Year-to-date, Sangamo Therapeutics, Inc. shares have moved 15.05%, while the 5-day performance has seen it change 5.13%. Over the past 30 days, the shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have changed -18.39%. Short interest in the company has seen 17.1 Million shares shorted with days to cover at 7.37.

Sangamo Therapeutics, Inc. (SGMO) estimates and forecasts

Figures show that Sangamo Therapeutics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +17.3% over the past 6 months, with this year growth rate of -81.18%, compared to 9.5% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 146.2% and -37.5% for the next quarter. Revenue growth from the last financial year stood is estimated to be +40.4%.

6 analysts offering their estimates for the company have set an average revenue estimate of $102.71 Million for the current quarter. 6 have an estimated revenue figure of $24.07 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $13.58 Million and $12.16 Million respectively for this quarter and the next, and analysts expect sales will grow by 656.3% for the current quarter and 97.9% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -16.6% over the past 5 years. Earnings growth for 2020 is a modest -20.4%.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO)’s Major holders

Insiders own 21.57% of the company shares, while shares held by institutions stand at 68.85% with a share float percentage of 87.78%. Investors are also buoyed by the number of investors in a company, with Sangamo Therapeutics, Inc. having a total of 263 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 9.38 Million shares worth more than $59.73 Million. As of March 30, 2020, Blackrock Inc. held 6.66% of shares outstanding.

The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 8.55 Million shares as of March 30, 2020. The firm’s total holdings are worth over $54.49 Million and represent 6.07% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Explorer Fund, Inc. As of March 30, 2020, the former fund manager holds about 2.43% shares in the company for having 3420678 shares of worth $21.79 Million while later fund manager owns 2.9 Million shares of worth $21.23 Million as of January 30, 2020, which makes it owner of about 2.06% of company’s outstanding stock.